Skip to content
Inciteful Med

The Science of Rare Skin Lupus: Genes and Biology

Last updated:

Rare forms of cutaneous (skin) lupus are caused by an overactive immune response where the body mistakes its own DNA for a viral infection. This constant 'interferon signature' drives subtypes like Chilblain Lupus, Bullous SLE, LEP, and LET, which may respond to targeted treatments.

Key Takeaways

  • • Rare skin lupus is driven by an overactive Type I interferon system that mistakenly identifies the body's own DNA as a viral threat.
  • • Chilblain Lupus (CHLE) is triggered by cold temperatures and can sometimes be linked to inherited mutations in the TREX1 gene.
  • • Bullous Systemic Lupus (BSLE) causes large skin blisters because autoantibodies attack the collagen that holds skin layers together.
  • • Lupus Erythematosus Profundus (LEP) involves severe inflammation in deep fat tissue, often leaving permanent dents or scars.
  • • Lupus Erythematosus Tumidus (LET) causes hive-like inflammation in the upper skin layers and is heavily triggered by sun exposure.

Rare forms of cutaneous lupus are not just “skin deep”; they are driven by complex biological errors where your immune system misidentifies your own DNA and proteins as threats. While each subtype looks different on the surface, they all belong to a family of diseases characterized by an overactive Type I Interferon system [1][2].

The “Interferon Signature”: An Internal Alarm

In a healthy body, Type I Interferon (IFN-I) is like a smoke alarm that goes off when a virus is detected. In lupus, this alarm is stuck “on” even when there is no infection [3]. This constant state of alert is called the interferon signature [4].

Specialized immune cells called plasmacytoid dendritic cells (pDCs) are the primary producers of this interferon [5][6]. They are found in high numbers in the skin of people with lupus, constantly pumping out signals that tell other immune cells to attack [7][8].

Why the Body Attacks Itself

The “fuel” for this interferon fire is often your own DNA. When cells are damaged by the sun or cold, they release DNA that isn’t cleaned up properly.

  • NETosis: White blood cells called neutrophils can release “webs” of DNA called Neutrophil Extracellular Traps (NETs) [9].
  • The Error: In lupus, these NETs are not cleared away. Instead, they are picked up by pDCs, which mistake them for a viral infection and trigger a massive interferon response [10][11].

Biology of the Rare Subtypes

Chilblain Lupus (CHLE) & the TREX1 Gene

In many families, Chilblain Lupus is caused by a mutation in the TREX1 gene [12].

  • The Mechanism: Normally, the TREX1 enzyme acts like a “garbage disposal” for DNA inside your cells [13].
  • The Failure: When TREX1 is mutated, “trash” DNA piles up inside the cell. A sensor called cGAS-STING detects this pileup and assumes a virus is present, leading to the overproduction of interferon [14][15]. This causes the painful, cold-triggered inflammation in your fingers and toes [16].
  • Genetics: If you have a strong family history of chilblains starting in childhood, your doctor may recommend genetic testing. However, sporadic (non-inherited) cases also occur, so a mutation is not always to blame, and testing is tailored to your individual and family history [12].

Bullous Systemic Lupus (BSLE) & Type VII Collagen

BSLE is unique because the immune system creates autoantibodies that specifically target Type VII collagen [17][18].

  • The Mechanism: Type VII collagen acts like “velcro,” holding the top layer of your skin (epidermis) to the layer beneath it (dermis) [19].
  • The Failure: When antibodies attack this “velcro,” the layers pull apart, and fluid rushes into the gap, creating large, tense blisters [20][21].

Lupus Erythematosus Profundus (LEP)

In LEP (also called Lupus Panniculitis), the attack happens deep in the fat layer.

  • The Mechanism: Research shows that NETs (those DNA webs) are found in massive amounts in the fat tissue of LEP patients [22].
  • The Failure: These NETs trigger intense inflammation that destroys fat cells, leading to the deep “dents” or scars characteristic of this variant [23][24].

Lupus Erythematosus Tumidus (LET)

LET is the most sun-sensitive variant [25].

  • The Mechanism: UV light causes skin cells to release nucleic acids (DNA/RNA) [26].
  • The Failure: Because people with LET have a high number of pDCs (the interferon-producing cells) in their skin, even a small amount of sun-damaged DNA can trigger a large, hive-like inflammatory response [27][28]. Unlike other forms, this usually stays in the upper skin layers and does not cause scarring [29].

Understanding these distinct biological pathways helps doctors move away from a “one-size-fits-all” approach and toward treatments that target the specific error in your immune system, such as JAK inhibitors that can “mute” the overactive interferon signal [12][30].

Frequently Asked Questions

What is the interferon signature in skin lupus?
The interferon signature is a constant state of immune system alert. In lupus, specialized cells overproduce a signal called Type I interferon as if fighting a viral infection, even when no actual virus is present.
Does Chilblain Lupus run in families?
Yes, some cases of Chilblain Lupus are inherited and linked to a mutation in the TREX1 gene. If you have a strong family history of chilblains starting in childhood, your doctor may recommend genetic testing to check for this mutation.
Why does Bullous Systemic Lupus cause skin blisters?
In Bullous Systemic Lupus, the immune system creates autoantibodies that attack Type VII collagen. This protein acts like velcro holding your skin layers together, and when it is damaged, fluid fills the gaps to create large, tense blisters.
What triggers Lupus Erythematosus Tumidus (LET) flare-ups?
LET is highly sensitive to the sun. Ultraviolet (UV) light causes skin cells to release DNA, which triggers a massive, hive-like inflammatory response from immune cells located in the upper layers of the skin.
Can JAK inhibitors treat rare skin lupus?
JAK inhibitors are a targeted therapy that can help mute the overactive interferon signals causing inflammation in the skin. Your doctor can determine if this is an appropriate option based on the specific biology of your lupus subtype.

Questions for Your Doctor

  • • Does my specific subtype of lupus suggest a 'Type I Interferon signature' in my blood or skin?
  • • Given my family history (if applicable), should I be tested for the TREX1 gene mutation?
  • • For Bullous SLE, what tests are you using to confirm the antibodies are targeting Type VII collagen?
  • • How does the presence of 'NETs' (Neutrophil Extracellular Traps) in my skin biopsy help guide my treatment plan?
  • • Are Janus Kinase (JAK) inhibitors a potential option for managing the interferon overproduction in my case?

Questions for You

  • • Do your symptoms flare up more after being in the sun (LET) or when you are exposed to cold temperatures (CHLE)?
  • • Have you noticed if your skin lesions appear after a small injury or 'trauma' to the skin (LEP)?
  • • Do other family members have similar 'cold sores' or skin issues on their fingers and toes?
  • • Are your blisters 'tense' and hard to pop, and have you noticed any sores inside your mouth?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Focus on Interferon Signature in Cutaneous Lupus Erythematosus: Novel Therapies From Better Understanding of the Pathogenesis.

    Gao M, Zhang N, Xia Y

    Journal of immunology research 2025; (2025()):5600731 doi:10.1155/jimr/5600731.

    PMID: 41098186
  2. 2

    Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus.

    Karnell JL, Wu Y, Mittereder N, et al.

    Science translational medicine 2021; (13(595)) doi:10.1126/scitranslmed.abf8442.

    PMID: 34039741
  3. 3

    Predominant Role of Plasmacytoid Dendritic Cells in Stimulating Systemic Autoimmunity.

    Huang X, Dorta-Estremera S, Yao Y, et al.

    Frontiers in immunology 2015; (6()):526 doi:10.3389/fimmu.2015.00526.

    PMID: 26528288
  4. 4

    NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus.

    Vorwerk G, Zahn S, Bieber T, Wenzel J

    Experimental dermatology 2021; (30(6)):847-852 doi:10.1111/exd.14311.

    PMID: 33687107
  5. 5

    Clearance Deficiency and Cell Death Pathways: A Model for the Pathogenesis of SLE.

    Mahajan A, Herrmann M, Muñoz LE

    Frontiers in immunology 2016; (7()):35 doi:10.3389/fimmu.2016.00035.

    PMID: 26904025
  6. 6

    Role of neutrophils in cutaneous lupus erythematosus.

    Yamamoto T

    The Journal of dermatology 2024; (51(2)):180-184 doi:10.1111/1346-8138.17036.

    PMID: 38009863
  7. 7

    Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T cell lymphoma.

    Chen SJT, Tse JY, Harms PW, et al.

    Histopathology 2019; (74(6)):908-916 doi:10.1111/his.13817.

    PMID: 30597607
  8. 8

    Ontogeny and Function of Plasmacytoid Dendritic Cells.

    Adams NM, Das A, Yun TJ, Reizis B

    Annual review of immunology 2024; (42(1)):347-373 doi:10.1146/annurev-immunol-090122-041105.

    PMID: 38941603
  9. 9

    Coordination between innate immune cells, type I IFNs and IRF5 drives SLE pathogenesis.

    Matta B, Barnes BJ

    Cytokine 2020; (132()):154731 doi:10.1016/j.cyto.2019.05.018.

    PMID: 31130331
  10. 10

    Neutrophils drive type I interferon production and autoantibodies in patients with Wiskott-Aldrich syndrome.

    Cervantes-Luevano KE, Caronni N, Castiello MC, et al.

    The Journal of allergy and clinical immunology 2018; (142(5)):1605-1617.e4 doi:10.1016/j.jaci.2017.11.063.

    PMID: 29447842
  11. 11

    At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases.

    Barnado A, Crofford LJ, Oates JC

    Journal of leukocyte biology 2016; (99(2)):265-78 doi:10.1189/jlb.5BT0615-234R.

    PMID: 26658004
  12. 12

    Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.

    Zimmermann N, Wolf C, Schwenke R, et al.

    JAMA dermatology 2019; (155(3)):342-346 doi:10.1001/jamadermatol.2018.5077.

    PMID: 30673078
  13. 13

    Meloxicam inhibits STING phosphorylation and alleviates intracellular DNA-mediated autoimmune responses.

    Yu Y, Wang M, Li XW, et al.

    Cell & bioscience 2023; (13(1)):76 doi:10.1186/s13578-023-01025-3.

    PMID: 37120570
  14. 14

    LINE-1: an emerging initiator of cGAS-STING signalling and inflammation that is dysregulated in disease.

    Mathavarajah S, Dellaire G

    Biochemistry and cell biology = Biochimie et biologie cellulaire 2024; (102(1)):38-46 doi:10.1139/bcb-2023-0134.

    PMID: 37643478
  15. 15

    A novel TREX1 inhibitor, VB-85680, upregulates cellular interferon responses.

    Flowers S, Petronella BA, McQueney MS, et al.

    PloS one 2024; (19(8)):e0305962 doi:10.1371/journal.pone.0305962.

    PMID: 39178223
  16. 16

    Chilblain lupus: A rare form of cutaneous lupus erythematosus - A case report.

    Perazzolli G, Banchetti E, Melis E, et al.

    SAGE open medical case reports 2026; (14()):2050313X261415591 doi:10.1177/2050313X261415591.

    PMID: 41625144
  17. 17

    Bullous systemic lupus erythematosus in females.

    Sprow G, Afarideh M, Dan J, et al.

    International journal of women's dermatology 2022; (8(3)):e034 doi:10.1097/JW9.0000000000000034.

    PMID: 35923586
  18. 18

    Complement System Part II: Role in Immunity.

    Merle NS, Noe R, Halbwachs-Mecarelli L, et al.

    Frontiers in immunology 2015; (6()):257 doi:10.3389/fimmu.2015.00257.

    PMID: 26074922
  19. 19

    Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy.

    Montagnon CM, Lehman JS, Murrell DF, et al.

    Journal of the American Academy of Dermatology 2021; (85(1)):18-27 doi:10.1016/j.jaad.2020.05.161.

    PMID: 33684494
  20. 20

    Successful treatment of bullous lupus with corticosteroids and belimumab: A case report.

    Keshavamurthy C, Fibeger E, Virata A, Bansal P

    Modern rheumatology case reports 2023; (7(1)):52-56 doi:10.1093/mrcr/rxac046.

    PMID: 35538618
  21. 21

    Unusual presentation of systemic lupus erythematosus.

    Mahesh E, Madhyastha PR, Varma V, et al.

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2017; (28(3)):653-656 doi:10.4103/1319-2442.206468.

    PMID: 28540909
  22. 22

    Investigating the presence of neutrophil extracellular traps in septal and lobular cutaneous panniculitides.

    Safi R, El Hasbani G, Bardawil T, et al.

    International journal of dermatology 2021; (60(6)):724-729 doi:10.1111/ijd.15450.

    PMID: 33580883
  23. 23

    Investigating the presence of neutrophil extracellular traps in cutaneous lesions of different subtypes of lupus erythematosus.

    Safi R, Al-Hage J, Abbas O, et al.

    Experimental dermatology 2019; (28(11)):1348-1352 doi:10.1111/exd.14040.

    PMID: 31529548
  24. 24

    Novel diagnostic imaging features of facial lupus panniculitis: ultrasound, CT, and MR imaging with histopathology correlate.

    Kimball H, Kimball D, Siroy A, et al.

    Clinical imaging 2019; (58()):177-181 doi:10.1016/j.clinimag.2019.07.006.

    PMID: 31386960
  25. 25

    Lupus Erythematosus Tumidus as a Distinct Uncommon Subtype of Cutaneous Lupus Erythematosus: A Case Report and Review.

    Camisa C, Papavero V

    Cureus 2024; (16(4)):e59140 doi:10.7759/cureus.59140.

    PMID: 38803774
  26. 26

    Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus.

    Fetter T, Braegelmann C, de Vos L, Wenzel J

    Frontiers in medicine 2022; (9()):915828 doi:10.3389/fmed.2022.915828.

    PMID: 35712102
  27. 27

    Lupus Erythematosus Tumidus: Clinical and Pathological Features in a Series of 20 Patients.

    Magaña M, Castellanos G, Meurehg CC, Magaña-Mainero MR

    The American Journal of dermatopathology 2022; (44(7)):469-477 doi:10.1097/DAD.0000000000002019.

    PMID: 35704910
  28. 28

    Clinical, Histopathological, and Therapeutic Features in Lupus Erythematosus Tumidus: A Retrospective Study.

    la Rotta-Higuera E, Morgado-Carrasco D, Mansilla-Polo M, et al.

    Actas dermo-sifiliograficas 2025; (116(6)):T628-T632 doi:10.1016/j.ad.2025.03.014.

    PMID: 40107417
  29. 29

    Dermoscopic Features of Acute, Subacute, Chronic and Intermittent Subtypes of Cutaneous Lupus Erythematosus in Caucasians.

    Żychowska M, Reich A

    Journal of clinical medicine 2022; (11(14)) doi:10.3390/jcm11144088.

    PMID: 35887849
  30. 30

    Familial chilblain lupus due to a gain-of-function mutation in STING.

    König N, Fiehn C, Wolf C, et al.

    Annals of the rheumatic diseases 2017; (76(2)):468-472 doi:10.1136/annrheumdis-2016-209841.

    PMID: 27566796

This page explains the biology and genetics of rare skin lupus for educational purposes only. Always consult your dermatologist or rheumatologist for a proper diagnosis and treatment plan tailored to your symptoms.

Stay up to date

Get notified when new research about Rare cutaneous lupus erythematosus is published.

No spam. Unsubscribe anytime.